Default company panoramic image
Logo

Omniox

Omniox focuses on alleviating disease-causing tissue hypoxia using a breakthrough oxygen carrier technology that overcomes prior failures

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded October 2006
  • Employees 8
  • Website omnioxinc.com

Company Summary

Omniox is a biotechnology company commercializing a breakthrough oxygen delivery protein technology called H-NOX to address diseases of peripheral hypoxia. Omniox products will be applied to a broad range of unmet clinical needs in cancer, cardiovascular diseases, and trauma. The H-NOX platform directly overcomes key reasons for the failure of prior oxygen delivery efforts, and has the potential to become a transformational medical technology.

Team

  • Default avatar
    Stephen Cary, Ph.D.
    CEO

    Dr. Cary co-founded Omniox in 2006. He spent five years at Genentech, first in Research on preclinical immunology and oncology disease models and then in Development as a development and market strategist.

  • Default avatar
    Michael Marletta, Ph.D.
    Chair SAB

    Dr. Marletta is the Chair of the Scientific Advisory Board. He is also the President and CEO of The Scripps Research Institute, Ida H. and Cecil M. Green Professor of Chemistry, and is a member of the Institute of Medicine and the National Academy of Sciences.

  • Default avatar
    Ajit Shah, Ph.D.
    Director

    Dr. Shah has a combined 24 years of experience as an entrepreneur, operating executive and venture capitalist. He is also the co-founder of Intuitive Surgical and on the UC Berkeley Engineering Advisory Board. Dr. Shah is recognized in Silicon Valley as an outstanding scientific and strategic advisor to start-ups.

Advisors

  • Default avatar
    Alan Mendelson (L&W) and Gladys Monroy (MoFo)
    Lawyer
    Unconfirmed
    Default avatar
    AccuStart
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Friends & Family
    Unconfirmed